Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
XmAb20717 · 1 trial · 28 indications
Treatment-related adverse events as assessed by CTCAE v4.03
| Arm | Type | Description |
|---|---|---|
| XmAb20717 | EXPERIMENTAL | XmAb20717 administered by intravenous dosing on Days 1 and 15 of each 28-day cycle for a total of two cycles |
| Name | Type | Description |
|---|---|---|
| XmAb20717 | BIOLOGICAL | Monoclonal bispecific antibody |
Inclusion Criteria: * Histologically or cytologically confirmed diagnosis of one of the following advanced solid tumors: PART A (Dose Escalation Cohorts) 1. Melanoma; 2. Breast carcinoma that is estrogen receptor, progesterone receptor, and Her2 negative (triple-negative breast cancer; TNBC); 3. ...
Top 20 of 51 competitors
XmAb20717 is an investigational monoclonal antibody being studied for the treatment of melanoma and other advanced solid tumors. It is currently in Phase 1 clinical development and is not yet approved by the FDA. The drug is being evaluated for its safety and potential anti-tumor activity in patients with selected advanced cancers.
XmAb20717 is a bispecific monoclonal antibody designed to target two immune checkpoint proteins, PD-1 and CTLA-4. By binding to both targets, it aims to modulate the immune system's response against tumor cells. This dual-targeting approach is being investigated in the context of advanced solid tumors, including melanoma.
XmAb20717 is being developed by Xencor, Inc., a biopharmaceutical company traded on the Nasdaq under the ticker symbol XNCR. Xencor is responsible for the clinical development of the drug, which is currently in Phase 1 trials for advanced solid tumors.
XmAb20717 is in Phase 1 clinical development. It is an investigational drug and has not received FDA approval. The Phase 1 study has been completed, and the drug is not currently in active clinical trials. Its safety and efficacy are still being evaluated.
XmAb20717 has been studied in a Phase 1 clinical trial with the identifier NCT03517488. This trial, titled "A Study of XmAb®20717 in Subjects With Selected Advanced Solid Tumors," enrolled 150 participants in the United States. The study included patients with melanoma and many other advanced solid tumor types.
XmAb20717 is the primary name for this investigational drug. It is also referred to as XmAb®20717 in clinical trial documentation. No other alternative names have been reported for this drug in the available information.